Fig. 5: METTL16-dependent propargylation.
a Scheme illustrating METTL16-dependent labeling in combination with MePMe-seq to identify METTL16 target sites. Isolated mRNA is propargylated in vitro using METTL16 and analyzed by NGS. To eliminate false positive hits from in vitro off-target effects of METTL16, only hits observed also in MePMe-seq are identified as METTL16 targets. b IGV browser coverage tracks for MAT2A-mRNA mapped by METT16-labeling in vitro (cyan) or MePMe-seq (purple), or control (gray). Arrow indicates orientation of coding strand. c Overlap of identified m6A sites in n = 2 independent METTL16-labeling experiments. d Consensus motif for sequences surrounding identified As after METTL16-dependent labeling in vitro. e Overlap of identified m6A sites in METTL16-dependent in vitro and metabolic labeling for sites present in n = 2 independent experiments with HS filtering.
